Product Code: 4656
KEY FINDINGS
Orthobiologics are substances that orthopedic surgeons use to help injuries heal more quickly. They are used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally available in the human body. When they are used in higher concentrations, orthobiologics substances help speed up the healing process.
The demand for rapid recovery coupled with reduced hospital stay is one of the main factors promoting the growth of this market. The global orthobiologics market is growing at a CAGR of 5.14% in the forecasting period 2019-2027.
MARKET INSIGHTS
The increasing rise in the geriatric population is giving rise to implantable medical devices thereby giving rise to conditions like arthritis thus boosting the growth of the market. According to the WHO, there has been a substantial rise in the global geriatric population; the group of people above 65 years of age is the fastest growing population segment. This segment is expected to grow from 13% in 2010 to 53% by 2022.
Although, the healthcare reorganizations are assessed to have affected the orthobiologics surgeons. Such organizations, restrict a doctor from owing future constructed hospitals. The law stops existing doctors owned facilities from further adding investors and thereby limiting the growth of the market.
Increasing disposable income globally is estimated to be one of the factors that are creating numerous expansion opportunities for the growth of the orthobiologics market and further leaving a positive impact.
REGIONAL INSIGHTS
The global orthobiologics market has been geographically segmented by four major regions, which are North America, Europe, Asia-Pacific and the Rest of World. The North America region is the dominating market in recent years due to increased awareness regarding biological implants and thereby leaving a positive impact on the market.
Also, in the US in 2016, around 53 million people are suffering from arthritis, and about 78 million people are suffering from low back and neck pain. The rising incidence of sports injuries coupled with an increase in diseases are further boosting the market demand.
COMPETITIVE ANALYSIS
AAP Implantate AG, Allosource, Amedica Corporation, Baxter International Inc., Conmed Corporation, Depuy Inc. (Acquired By Johnson And Johnson), Exactech Inc., Integra Lifesciences Holding Corporation, Medtronic Inc., Nuvasive Inc., RTI Surgical Sanofi, Smith & Nephew Plc, Stryker Corporation and Zimmer Biomet Inc. are the major companies mentioned in the report.
Table of Contents
1. RESEARCH SCOPE
- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
- 2.1. SOURCES OF DATA
- 2.1.1. SECONDARY DATA
- 2.1.2. PRIMARY DATA
- 2.2. TOP-DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
- 3.1. MARKET SUMMARY
- 3.2. KEY FINDINGS
- 3.2.1. HOSPITALS ARE THE LARGEST REVENUE GENERATING END-USER
- 3.2.2. SPINAL FUSION IS THE FASTEST GROWING APPLICATION
- 3.2.3. VISCOSUPPLEMENTATION HOLDS THE LARGEST MARKET SHARE IN TERMS OF PRODUCTS
4. MARKET DYNAMICS
- 4.1. MARKET SCOPE & DEFINITION
- 4.2. MARKET DRIVERS
- 4.2.1. SURGING DEMAND FOR SPINAL FUSION SURGERIES
- 4.2.2. INCREASING GERIATRIC POPULATION
- 4.2.3. INCREASE ORTHOPAEDIC RELATED DISEASES DUE TO LIFESTYLE CHOICES
- 4.2.4. TECHNOLOGICAL ADVANCEMENT
- 4.3. MARKET RESTRAINTS
- 4.3.1. STRINGENT GOVERNMENT POLICIES
- 4.3.2. POST-SURGERY COMPLICATIONS
- 4.3.3. HIGH COST OF ORTHOPEDICS IMPLANTS
- 4.4. MARKET OPPORTUNITIES
- 4.4.1. INCREASED UTILIZATION OF BONE REGENERATION TECHNOLOGY
- 4.4.2. GROWING DISPOSABLE INCOME
- 4.4.3. EXPANSION OF COST EFFECTIVE MEDICAL PRODUCTS
- 4.4.4. HUGE MARKET OPPORTUNITIES IN DEVELOPING COUNTRIES
- 4.5. MARKET CHALLENGES
- 4.5.1. HIGH COST OF SPINAL FUSION SURGERY
- 4.5.2. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE
5. MARKET BY END-USER
- 5.1. HOSPITALS
- 5.2. ORTHOPEDIC CLINICS
6. MARKET BY PRODUCTS
- 6.1. DEMINERALIZED BONE MATRIX (DBM)
- 6.2. ALLOGRAFT
- 6.3. BONE MORPHOGENETIC PROTEIN (BMP)
- 6.4. VISCOSUPPLEMENTATION
- 6.4.1. ONE-INJECTION
- 6.4.2. THREE-INJECTION
- 6.4.3. FIVE-INJECTION
- 6.5. SYNTHETIC BONE SUBSTITUTES
- 6.6. STEM CELL THERAPY
- 6.7. OTHER PRODUCTS
7. MARKET BY APPLICATION
- 7.1. SPINAL FUSION
- 7.2. TRAUMA REPAIR
- 7.3. RECONSTRUCTIVE SURGERY
- 7.4. TENDON AND LIGAMENT
- 7.5. OTHER APPLICATIONS
8. KEY ANALYTICS
- 8.1. PORTER'S FIVE FORCE MODEL
- 8.1.1. THREAT OF NEW ENTRANTS
- 8.1.2. THREAT OF SUBSTITUTE
- 8.1.3. BARGAINING POWER OF BUYER
- 8.1.4. BARGAINING POWER OF SUPPLIER
- 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 8.2. PESTEL ANALYSIS
- 8.3. PATENT ANALYSIS
- 8.4. KEY BUYING CRITERIA
- 8.5. VALUE CHAIN ANALYSIS
- 8.6. OPPORTUNITY MATRIX
9. GEOGRAPHICAL ANALYSIS
- 9.1. NORTH AMERICA
- 9.1.1. THE UNITED STATES
- 9.1.2. CANADA
- 9.2. EUROPE
- 9.2.1. THE UNITED KINGDOM
- 9.2.2. FRANCE
- 9.2.3. GERMANY
- 9.2.4. SPAIN
- 9.2.5. ITALY
- 9.2.6. REST OF EUROPE
- 9.3. ASIA-PACIFIC
- 9.3.1. INDIA
- 9.3.2. CHINA
- 9.3.3. JAPAN
- 9.3.4. AUSTRALIA
- 9.3.5. SOUTH KOREA
- 9.3.6. REST OF ASIA-PACIFIC
- 9.4. REST OF WORLD
- 9.4.1. LATIN AMERICA
- 9.4.2. MIDDLE EAST AND AFRICA
10. COMPETITIVE LANDSCAPE
- 10.1. MARKET SHARE ANALYSIS
- 10.2. COMPANY PROFILES
- 10.2.1. AAP IMPLANTATE AG
- 10.2.1.1. COMPANY OVERVIEW
- 10.2.1.2. PRODUCT PORTFOLIO
- 10.2.1.3. SCOT ANALYSIS
- 10.2.2. ALLOSOURCE
- 10.2.2.1. COMPANY OVERVIEW
- 10.2.2.2. PRODUCT PORTFOLIO
- 10.2.2.3. SCOT ANALYSIS
- 10.2.2.4. STRATEGIC INITIATIVE
- 10.2.3. AMEDICA CORPORATION
- 10.2.3.1. COMPANY OVERVIEW
- 10.2.3.2. PRODUCT PORTFOLIO
- 10.2.3.3. SCOT ANALYSIS
- 10.2.3.4. STRATEGIC INITIATIVES
- 10.2.4. BAXTER INTERNATIONAL INC.
- 10.2.4.1. MARKET OVERVIEW
- 10.2.4.2. PRODUCT PORTFOLIO
- 10.2.4.3. SCOT ANALYSIS
- 10.2.4.4. STRATEGIC INITIATIVES
- 10.2.5. CONMED CORPORATION
- 10.2.5.1. COMPANY OVERVIEW
- 10.2.5.2. PRODUCT PORTFOLIO
- 10.2.6. DEPUY INC. (ACQUIRED BY JOHNSON AND JOHNSON)
- 10.2.6.1. COMPANY OVERVIEW
- 10.2.6.2. PRODUCT PORTFOLIO
- 10.2.6.3. SCOT ANALYSIS
- 10.2.6.4. STRATEGIC INITIATIVES
- 10.2.7. EXACTECH INC.
- 10.2.7.1. COMPANY OVERVIEW
- 10.2.7.2. PRODUCT PORTFOLIO
- 10.2.7.3. STRATEGIC INITIATIVES
- 10.2.8. INTEGRA LIFESCIENCES HOLDING CORPORATION
- 10.2.8.1. COMPANY OVERVIEW
- 10.2.8.2. PRODUCT PORTFOLIO
- 10.2.8.3. SCOT ANALYSIS
- 10.2.8.4. STRATEGIC INITIATIVES
- 10.2.9. MEDTRONIC INC.
- 10.2.9.1. COMPANY OVERVIEW
- 10.2.9.2. PRODUCT PORTFOLIO
- 10.2.9.3. STRATEGIC INITIATIVES
- 10.2.10. NUVASIVE INC.
- 10.2.10.1. COMPANY OVERVIEW
- 10.2.10.2. PRODUCT PORTFOLIO
- 10.2.10.3. SCOT ANALYSIS
- 10.2.10.4. STRATEGIC INITIATIVES
- 10.2.11. RTI SURGICAL
- 10.2.11.1. COMPANY OVERVIEW
- 10.2.11.2. PRODUCT PORTFOLIO
- 10.2.11.3. SCOT ANALYSIS
- 10.2.11.4. STRATEGIC INITIATIVES
- 10.2.12. SANOFI
- 10.2.12.1. COMPANY OVERVIEW
- 10.2.12.2. PRODUCT PORTFOLIO
- 10.2.12.3. SCOT ANALYSIS
- 10.2.12.4. STRATEGIC INITIATIVES
- 10.2.13. SMITH & NEPHEW PLC
- 10.2.13.1. COMPANY OVERVIEW
- 10.2.13.2. PRODUCT PORTFOLIO
- 10.2.13.3. STRATEGIC INITIATIVES
- 10.2.14. STRYKER CORPORATION
- 10.2.14.1. COMPANY OVERVIEW
- 10.2.14.2. PRODUCT PORTFOLIO
- 10.2.14.3. STRATEGIC INITIATIVES
- 10.2.15. ZIMMER BIOMET INC.
- 10.2.15.1. COMPANY OVERVIEW
- 10.2.15.2. PRODUCT PORTFOLIO
- 10.2.15.3. SCOT ANALYSIS
- 10.2.15.4. STRATEGIC INITIATIVES